Currently Viewing:
American Society of Clinical Oncology (ASCO) 2017
Dr Barbara McAneny on How the COME HOME Model Helps Cut Hospitalization Rates
June 14, 2017
Real-World Treatment Patterns Highlight Need for Clinical Education on PD-L1 Testing in NSCLC
June 13, 2017
Can the 4 Ps Devise Interventions to Reduce the Financial Toxicity of Cancer?
June 06, 2017
Dr Barbara McAneny Outlines Collaboration With ASCO on COME HOME Model
June 05, 2017
Daratumumab With Standard Regimen Improves PFS in Multiple Myeloma, Independent of Cytogenetic Risk
June 05, 2017
Currently Reading
MACRA 2.0 and Beyond: Preparing Your Practice to Meet the Quality and Reporting Challenges
June 05, 2017
Dr Edward Li Discusses the Benefit Biosimilars Can Have in Oncology
June 04, 2017
Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer
June 04, 2017
Do We Have Adequate Surveillance in Cancer Survivor Care?
June 04, 2017
Dr Basit Chaudhry on Experiences in the Oncology Care Model and Early Indications of Success
June 04, 2017
Dr Scott Ramsey: Value Frameworks Are Moving Toward Harmonization
June 03, 2017
Physician, Regulatory, and Payer Perspectives on the Value of Real-World Data
June 03, 2017
Patient Selection Vital in Ensuring Improved Response to PD-1, PD-L1 Inhibitors in NSCLC
June 03, 2017
Dr Daniel George Highlights Successes of Checkpoint Inhibitors in Prostate, Bladder Cancers
June 03, 2017
ASCO Study Finds Shift in Diagnosis Stage for Several Cancers Following ACA Implementation
June 01, 2017
HPV Vaccination May Lower Prevalence of Oropharyngeal Cancers in Young Adults
May 31, 2017

MACRA 2.0 and Beyond: Preparing Your Practice to Meet the Quality and Reporting Challenges

Surabhi Dangi-Garimella, PhD
At the 2017 American Society of Clinical Oncology Annual Meeting, oncologists heard from fellow experts on the best way to navigate this daunting payment reform challenge.
Explaining the cost reporting basics, Polite said that the per capita cost measures will be risk-adjusted by specialty. It currently includes 41 episode measures, none of which are oncology-related. The measures include the cost of Medicare Part B drugs, while Part D drugs have been excluded.

“CMS is still working with issues such as defining an episode, and ASCO is working with CMS to provide feedback and help develop the reimbursement model,” Polite told the audience.

He went on to urge the oncologists in the room to take concrete steps to work with CMS on QPP reporting, although in 2017, CMS has allowed practices to “pick their pace.” The options that are available include:
  • Practices that don’t participate in the QPP reporting program in 2017 will see a negative 4% payment adjustment in 2019.
  • Practices that test the program and report 1 quality measure or IA or the required ACI measures (which, Polite said should be the least a practice should do in 2017) can avoid penalties in 2019.
  • If the practice is involved in partial MIPS reporting in 2017, meaning it reports on more than 1 quality measure, or IA or more than the required ACI, it can avoid penalties and be eligible for partial positive payment adjustment in 2019.
  • Practices that take on full MIPS reporting in 2017 can avoid penalties and be eligible for partial positive payment adjustment as well as an exceptional performance bonus in 2019.

Barbara McAneny, MD, provided a historic perspective on the evolution of payment models, showing the top-down versus the bottom-up models, which are payer-driven and provider-driven, respectively. The provider-driven model, where the practice identifies problems that lead to changes with the way payers pay for care, is more patient-centric and is geared to reduce financial toxicity for patients.

“We looked at things in our clinic that we can influence, such as hospital admission and triage to manage toxicities and avoiding sending the patients to the emergency room,” McAneny said, and that resulted in the COME HOME pilot, which received a CMS funding grant.



 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!